Shenouda Maged's most recent trade in Relmada Therapeutics Inc was a trade of 828,000 Stock Appreciation Rights done . Disclosure was reported to the exchange on Dec. 12, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Dec 2025 | 828,000 | 828,000 | - | - | Stock Appreciation Rights | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.12 per share. | 12 Dec 2025 | 11,665 | 800,000 (5%) | 0% | 4.1 | 48,060 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.20 per share. | 05 Nov 2025 | 500,000 | 788,335 (5%) | 3% | 2.2 | 1,100,000 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 600,000 | 600,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.49 per share. | 16 May 2025 | 90,000 | 228,335 (1%) | 0% | 0.5 | 43,686 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.52 per share. | 16 May 2025 | 60,000 | 288,335 (1%) | 0% | 0.5 | 31,422 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 0.44 per share. | 16 May 2025 | 50,000 | 138,335 (0%) | 0% | 0.4 | 22,100 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.95 per share. | 09 Sep 2024 | 24,120 | 88,335 (0%) | 0% | 3.0 | 71,154 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.73 per share. | 09 Sep 2024 | 21,118 | 64,215 (0%) | 0% | 2.7 | 57,652 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 2.55 per share. | 09 Sep 2024 | 8,194 | 43,097 (0%) | 0% | 2.6 | 20,895 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 54,624 | 136,714 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Other type of transaction at price $ 0.00 per share. | 24 May 2024 | 54,624 | 82,090 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Shenouda Maged | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.89 per share. | 29 Jan 2024 | 15,000 | 28,028 (0%) | 0% | 3.9 | 58,323 | Common Stock |
| Relmada Therapeutics Inc | Shenouda Maged | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.65 per share. | 29 Jan 2024 | 10,800 | 13,028 (0%) | 0% | 3.7 | 39,450 | Common Stock |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 4.06 per share. | 29 Jan 2024 | 6,875 | 34,903 (0%) | 0% | 4.1 | 27,943 | Common Stock |
| Relmada Therapeutics Inc | Shenouda Maged | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 82,090 | 82,090 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 317,643 | 512,560 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | CFO | Other type of transaction at price $ 0.00 per share. | 16 Dec 2022 | 200,000 | 0 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 194,917 | 194,917 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 295,211 | 522,729 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2022 | 200,000 | 200,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Maged Shenouda | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 227,518 | 227,518 | - | - | Stock Option (right to buy) |